gi-hepatology
Baveno VII Criteria — Compensated Advanced Chronic Liver Disease (cACLD)
Baveno VII consensus (de Franchis 2022) for non-invasive identification of cACLD and clinically significant portal hypertension (CSPH) using liver stiffness measurement (LSM) by transient elastography and platelet count. 'Rule of 5' for LSM categories.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Propranolol (Portal Hypertension) · Antihypertensive
- Carvedilol (Portal Hypertension) · Non-Selective Beta-Blocker with Alpha₁-Blocking Activity
- Methyldopa (Chronic Hypertension in Pregnancy) · Centrally Acting Antihypertensive
- Amlodipine · Dihydropyridine Calcium Channel Blocker — Raynaud's / Peripheral Vascular Disease / Hypertension
- Hydralazine · Direct-Acting Vasodilator — Hypertensive Emergency / Chronic Hypertension
- Selexipag · Pulmonary Arterial Hypertension
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.